Target 2035 Webinar
Targeting Deubiquitinases for Therapeutic Benefit
Co-opting the Ubiquitin/Proteasome System is an emerging therapeutic strategy, as demonstrated by Cereblon E3 Ligase Modifying Drugs (CELMoDs), Selective Estrogen Receptor Degraders (SERDs), and heterobifunctional degraders in the clinic. Deubiquitinases (DUBs) are a class of proteases that disassemble ubiquitin chains and remove ubiquitin moieties from target proteins. We will discuss strategies for targeting deubiqutinases, with an emphasis on achieving potency and specificity to achieve maximal therapeutic benefit.
Hosted by Ingrid Wertz (Bristol Myers Squibb)
Speakers: Sara Buhrlage (Dana-Farber Cancer Institute) and Anthony Varca (Dana-Farber Cancer Institute)
Tuesday 20 September 2022 at 7 am PDT / 10 am EDT / 3 pm BST / 4 pm CEST
